Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH treatment in such children

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Glucocorticosteroid treatment for 12 months at least

• Bone age < 15 years for a boy and < 13 years for a girl

• Child measured height < - 2 SD, Child currently treated by GH

Exclusion Criteria:

• Known diabetes (type 1 or type 2)

• A previous history of intolerance or hypersensitivity to the study drug or to drugs with similar chemical structures